PubMed Daily Triage Digest — 2026-07-15

Run: attempt1-20260715T090000Z | Window: 2026-07-14 09:00 UTC → 2026-07-15 09:00 UTC
Schema: v1.3 | Status: complete | Articles in output: 32

📊 Coverage Summary

🔴 HIGH Priority Articles (score 7–9)

Score 9 — GPRC5D CAR-T Dominates Post-BCMA Myeloma

[42448658] Kang Y et al. "Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis." Blood Cancer Journal (2026-07-14). DOI: 10.1038/s41408-026-01564-1

• Key finding: GPRC5D-targeted CAR-T: 86% ORR vs 66% for BCMA CAR-T (p=0.0006) and 52% for antibodies in post-BCMA R/R MM; interval ≥10 months between BCMA and subsequent therapy correlates with better outcomes (70% vs 50% ORR)
• Design: Systematic review + meta-analysis; 34 studies, n=1280
• Topics: T1 (Hematologic Malignancies), T6 (Novel Therapeutics)
• Triage: N=3 D=2 P=2 E=2 | Access: open_access

Score 8 — AML Oncogene Dosage Checkpoint (NMD)

[42448936] Zhang M et al. "EIF4A3-dependent nonsense-mediated decay buffers AML1-ETO9a dosage and modulates outcome in t(8;21) acute myeloid leukemia." Leukemia (2026-07-14). DOI: 10.1038/s41375-026-03051-9

• Key finding: EIF4A3-dependent NMD restrains the oncogenic AE9a isoform; high EIF4A3 predicts improved OS specifically in t(8;21) AML and enhances idarubicin sensitivity
• Design: Basic + translational (cell lines + primary patient cells + clinical OS correlation)
• Topics: T1 (Hematologic Malignancies)
• Triage: N=3 D=1 P=2 E=2 | Access: subscription

Score 8 — Blood Biomarkers Predict AD Conversion in Down Syndrome

[42449162] Zhang F et al. "Blood biomarkers predict conversion from cognitively stable to MCI or Alzheimer's disease in Down syndrome at 16-month follow-up in ABC-DS." Alzheimer's & Dementia (2026-07-14). DOI: 10.1002/alz.71659

• Key finding: 13-plasma-biomarker SVM achieves 92.4% sensitivity, AUC 0.779 for predicting MCI/AD conversion 16 months ahead in Down syndrome (n=246, longitudinal)
• Design: Multi-site prospective longitudinal cohort (ABC-DS consortium)
• Topics: T9 (Rare Diseases), T8 (Aging), Sentinel
• Triage: N=3 D=2 P=2 E=1 | Access: open_access

Score 8 — PRS Stratifies CRC Lifetime Risk, Enables Earlier Screening Initiation

[42449149] Nøhr AK et al. "Combining genome-wide polygenic scores with registry data for colorectal cancer risk-based screening." British Journal of Cancer (2026-07-15). DOI: 10.1038/s41416-026-03532-9

• Key finding: High-PRS individuals reach low-PRS lifetime CRC incidence levels up to 10 years earlier; PRS stratifies risk across ancestries and tumor types; PRS+FIT combination adds limited marginal value at first screening
• Design: Population registry cohort, n=112,204 with genomic + health registry data
• Topics: Sentinel, T5 (Precision Oncology)
• Triage: N=2 D=2 P=2 E=2 | Access: open_access

Score 7 — Selinexor + Ruxolitinib Overcomes JAK2 Resistance in Myelofibrosis

[42448318] Kashyap T et al. "Targeting nuclear export and JAK/STAT signalling in myelofibrosis…" British Journal of Haematology (2026-07-14). DOI: 10.1111/bjh.70639

• Key finding: XPO1 inhibitor selinexor retains activity in ruxolitinib-resistant MPN cells; combination with ruxolitinib shows additive anti-MF effects and reduces TNFα, IL-6, MCP-1 in patient PBMCs
• Topics: T1 | N=3 D=1 P=2 E=1 | Access: open_access

Score 7 — BrECADD Confirmed in Real-World Advanced Hodgkin Lymphoma

[42448612] Porges T et al. "Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study." British Journal of Haematology (2026-07-14). DOI: 10.1111/bjh.70682

• Key finding: 100% ORR, 95% CR, 96% 1-year PFS, 100% 1-year OS in 100 real-world advanced-stage cHL patients (19 centres, 80% stage IV); 83% PET-2 negativity enabling de-escalation from 6→4 cycles
• Topics: T1 | N=2 D=2 P=1 E=2 | Access: open_access

Score 7 — Burkitt Lymphoma: Molecular Subtypes, Global Survival Gap, Roadmap

[42448305] Khan AS et al. "Burkitt Lymphoma: Current Understanding, Unmet Needs, and Research Directions." Blood Advances (2026-07-14). DOI: 10.1182/bloodadvances.2024015620

• Key finding: EBV+/EBV− BL subtypes have distinct biology; survival rarely exceeds 50% in sub-Saharan Africa vs high curability in high-income settings; genomic insights enable scalable diagnostics and targeted therapy candidates
• Topics: T1 | N=2 D=1 P=2 E=2 | Access: subscription

Score 7 — HTLV-1 HBZ-DHX9 Axis Drives Pro-Survival circRNA in ATLL

[42448285] Ladet J et al. "HTLV-1 HBZ inhibits DHX9 to reprogram circRNA biogenesis in ATLL." Tumour Virus Research (2026-07-14). DOI: 10.1016/j.tvr.2026.200347

• Key finding: HBZ inhibits RNA helicase DHX9, promoting back-splicing of circRNAs including pro-survival circAFF2(3) in aggressive ATLL; silencing circAFF2(3) reduces leukemic cell survival
• Topics: T1 | N=3 D=1 P=2 E=1 | Access: subscription

Score 7 — AdvanTIG-302 Phase 3: Anti-TIGIT Fails to Improve OS in PD-L1 ≥50% NSCLC

[42448175] Socinski MA et al. "AdvanTIG-302: Phase 3 Study of Ociperlimab + Tislelizumab Versus Pembrolizumab in Untreated NSCLC With PD-L1 ≥50%." Journal of Thoracic Oncology (2026-07-14). DOI: 10.1016/j.jtho.2026.104089

• Key finding: Ociperlimab+tislelizumab shows no OS benefit vs pembrolizumab (HR 0.97, 95% CI 0.76–1.23); trial terminated for futility at N=662. Adds to mounting TIGIT Phase 3 failure pattern.
• Topics: T6 | N=2 D=2 P=2 E=1 | Access: subscription

Score 7 — SMARCAL1 Synthetic Lethality in ALT-Positive Tumors (Osteosarcoma)

[42448564] Taglialatela A et al. "SMARCAL1 is a candidate therapeutic target for ALT-positive tumors." Genes & Development (2026-07-14). DOI: 10.1101/gad.353377.125

• Key finding: SMARCAL1 is a selective essential dependency in ALT-positive (telomerase-negative) cancer cells; its depletion induces senescence, rendering ALT+ cells susceptible to senolytics; validated in osteosarcoma PDXs
• Topics: T5, T9 | N=3 D=1 P=2 E=1 | Access: open_access

Score 7 — Olink Proteomics Identifies CES3, LILRB4 for Early Pancreatic Cancer (AUC=0.91)

[42447929] Lin Y et al. "Plasma Protein Biomarkers for Early Detection of Pancreatic Cancer." International Journal of Cancer (2026-07-14). DOI: 10.1002/ijc.70637

• Key finding: From 5419 proteins screened (Olink Explore HT), CES3 and LILRB4 each achieve AUC=0.91 for stage I-II pancreatic cancer detection (n=42 cases, 43 matched controls); PPY has anatomical specificity for head tumors
• Topics: T3, T5 | N=3 D=1 P=2 E=1 | Access: subscription

Score 7 — MitralVision: DL Detects MR from Single-View B-Mode Echo (AUROC 0.91)

[42448004] Sandler RA et al. "Automated Detection of Clinically Significant Mitral Regurgitation from Single-View B-mode Echocardiography Using Deep Learning." Journal of the American Society of Echocardiography (2026-07-14). DOI: 10.1016/j.echo.2026.07.004

• Key finding: MitralVision DL model achieves AUROC 0.91, sensitivity 82.1%, specificity 84.3% for moderate/severe MR without Doppler input; validated on 629 studies from 26 external sites
• Topics: T4 | N=3 D=2 P=1 E=1 | Access: subscription

Score 7 — FGFR4-Targeted ADC Eradicates Relapsed Rhabdomyosarcoma in Preclinical Models

[42447867] Tian M et al. "Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers." Cell Reports Medicine (2026-07-14). DOI: 10.1016/j.xcrm.2026.102922

• Key finding: FGFR4-targeted exatecan-ADC (3A11 binder) achieves durable tumor control and retreatment efficacy in fusion-positive and fusion-negative RMS CDX/PDX models; paired to ongoing NCI CAR-T trial (NCT06865664)
• Topics: T6, T9 | N=3 D=1 P=2 E=1 | Access: open_access

Score 7 — ED-Foundation: Unified Multimodal AI for End-to-End Emergency Care

[42448807] Huang Z et al. "A unified multi-modal foundation model for end-to-end emergency care." npj Digital Medicine (2026-07-14). DOI: 10.1038/s41746-026-02981-z

• Key finding: BEIT-3-based ED-Foundation achieves state-of-the-art performance across 9 downstream emergency care datasets (triage, outcome prediction, decision support) and is robust to modality missingness
• Topics: T4 | N=3 D=2 P=1 E=1 | Access: open_access

Score 7 — Commercial AI for Pulmonary Nodule CT: Systematic Review Shows Evidence Gaps

[42448899] Paramasamy J et al. "Scientific evidence of commercial artificial intelligence products for pulmonary nodule assessment on CT scans: a systematic review." European Radiology (2026-07-15). DOI: 10.1007/s00330-026-12745-8

• Key finding: 95-study systematic review (2012–2024, RADAR framework): commercial CT AI for lung nodule has matured but all studies have high bias risk in ≥1 domain; 63% involve vendor funding; patient outcome/cost-effectiveness data minimal
• Topics: T4 | N=2 D=2 P=1 E=2 | Access: open_access

Score 7 — Only 8% of Multimodal Clinical AI Studies Assess Fairness (Systematic Review)

[42448927] Saha A et al. "Fairness in multimodal machine learning applications in clinical decision support: a systematic review." npj Digital Medicine (2026-07-14). DOI: 10.1038/s41746-026-03000-x

• Key finding: Of 88 multimodal CDS studies in chest X-ray/sepsis applications, only 8% assessed fairness despite 83% having sensitive attribute data available; 29 different fairness measurement approaches used across the field
• Topics: T4 | N=2 D=2 P=1 E=2 | Access: open_access

🟡 MEDIUM Priority Articles (score 4–6)

Additional MEDIUM Priority Articles (score 4)

⚪ LOW Priority Articles (score 1–3)

🚨 Notable Signals & Observations

T2 Zero-Result Gap

Both the primary CBC + ML query and the [tiab]-qualified fallback returned zero results for the 2026-07-14 to 2026-07-15 CRDT window. This is a legitimate search gap—not a pipeline failure. The Pulse team may want to consider broadening T2 query terms (e.g., dropping "hematology analyzer" requirement, adding "cell morphology" without the ML constraint) for future runs.

TIGIT Inhibitor Pattern

AdvanTIG-302 (PMID 42448175) terminated for futility confirms an emerging pattern of Phase 3 failures for anti-TIGIT agents in PD-L1-high NSCLC. This class of agents has now failed in multiple first-line settings; the oncology field appears to be retreating from TIGIT co-inhibition for this indication.

CAR-T Treatment Sequencing in Myeloma (Highest Score Day)

The GPRC5D CAR-T meta-analysis (PMID 42448658, score 9) provides the first large evidence base for post-BCMA antigen selection. The ≥10-month interval rule and GPRC5D superiority are immediately actionable clinical decisions.

Down Syndrome + Alzheimer's Biomarker

PMID 42449162 represents a high-signal rare disease + aging intersection: DS adults are an obligate AD-risk population with no current standard blood-based screening, and this multi-site cohort achieves 92.4% sensitivity 16 months pre-conversion. Monitor for external validation cohort.

EIF4A3-NMD Axis in AML (Leukemia)

PMID 42448936 identifies a novel RNA surveillance mechanism controlling oncogenic dosage in t(8;21) AML with direct clinical outcome correlation—one of the most mechanistically elegant translational discoveries of the window.

📋 Run Metadata

• API: NCBI E-utilities with API key (10 req/sec rate limit)
• Articles with full abstract data: 32/32
• Title-only conservative scoring applied: 0 (all articles have abstracts)
• Cross-topic articles: 42448658 (T1+T6), 42449162 (T9+T8+Sentinel), 42449149 (Sentinel+T5), 42447867 (T6+T9), 42448564 (T5+T9), 42447982 (T5+T7), 42445959 (T8+T7), 42448928 (T7+T8)
• Excluded from sentinel: 42449136 (CNN for geomorphology—non-biomedical)
• Schema validation: v1.3 (score_breakdown sums verified, pipeline_priority matches score, per_topic_stats complete)